Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

England’s NICE Rejects Tecentriq In Triple-Negative Breast Cancer

But the HTA body plans to work with Roche to address issues

Executive Summary

NICE draft guidance says that Tecentriq in combination with chemotherapy is not cost effective in untreated advanced triple-negative breast cancer.

You may also be interested in...



Triple-Negative Breast Cancer First In England As NICE Reverses Tecentriq Rejection

Roche has resolved the issues raised by the health technology assessment body over what is the first immunotherapy approved  for treating this aggressive and difficult-to-treat form of breast cancer.

NICE Rejects Tecentriq For Small-Cell Lung Cancer In England

Roche’s Tecentriq has been rejected by health technology assessment body NICE for use in small-cell lung cancer on the National Health Service. The move follows an earlier knockback for the drug in PD L1-positive triple-negative breast cancer.

Tecentriq Takes EU Lead In Triple-Negative Breast Cancer

Roche’s checkpoint inhibitor has been approved in combination with nab-paclitaxel in the EU for triple-negative breast cancer, cementing the company’s role as an innovator in breast cancer therapies.

Topics

Related Companies

UsernamePublicRestriction

Register

LL043624

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel